


Dr. Loren Walensky, MD
Dr. Loren Walensky, MD is a pediatric hematologist oncologist in Boston, MA and has over 25 years of experience in the medical field. He graduated from Johns Hopkins School of Medicine in 1997. He is affiliated with Boston Children's Hospital. He is accepting new patients.
Dana-Farber Cancer Institute
450 Brookline Ave Boston, MA 02215Care Philosophy
- Dr. Loren Walensky, MD
At a Glance
- Area of Expertise

Save money with free prescription discounts
Experience Check
Search for experience in a specific area
Insurance Check
Search for your insurance carrier and choose your plan type
Dr. Walensky's Reviews
Likelihood to recommend Dr. Walensky
5.0
5 Star | 100% | 100% |
4 Star | 0% | 0% |
3 Star | 0% | 0% |
2 Star | 0% | 0% |
1 Star | 0% | 0% |
Leave a review
How was your experience with Dr. Walensky?Overall Patient Satisfaction
Likelihood of recommending Dr. Walensky to family and friends is 5 out of 5
About Me
care philosophy
Dr Walensky received his MD and PhD degrees from Johns Hopkins University School of Medicine in 1997. He trained at the Boston Combined Residency Program in pediatrics, completed a fellowship in pediatric hematology-oncology at Dana-Farber and...read morebiography
Dr. Walensky received his MD and PhD degrees from Johns Hopkins University School of Medicine in 1997. He trained at the Boston Combined Residency Program in pediatrics, completed a fellowship in pediatric hematology-oncology at Dana-Farber and...read morePediatric Hematology & Oncology
*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.
Boston Children's Hospital/dana-farber Cancer Institute, Pediatric Hematology/oncology
Fellowship HospitalBoston Children's Hospital/boston Medical Center
Residency HospitalJohns Hopkins School Of Medicine
Medical School, 1997
Healthgrades receives board action history for physicians and physician assistants. The information displayed here is sourced from independent information providers, such as state board websites, and may not be the most up-to-date information. Healthgrades makes no representations with respect to the accuracy of any information provided here and assumes no responsibility or liability for such information.
Learn more about medical license public record checkInhibition of Pro-Apoptotic BAX by a Noncanonical Interaction Mechanism, 2015-02-12
Hydrocarbon-stitched Peptide Agonists of Glucagon-Like Peptide-1 Receptor, 2020-05-27
Biophysical Determinants for Cellular Uptake of Hydrocarbon-Stapled Peptide Helices, 2016-08-22
MCL-1 is a master regulator of cancer dependency on fatty acid oxidation, 2022-10-04
BH3-Triggered Structural Reorganization Drives the Activation of Pro-apoptotic BAX, 2010-11-12
Targeted Disruption of the BCL9/ß-catenin Complex Inhibits Oncogenic Wnt Signaling, 2012-08-22
Targeting a Helix-in-Groove Interaction Between E1 and E2 Blocks Ubiquitin Transfer, 2020-08-17
Phospho-BAD BH3 Mimicry Protects ß Cells and Restores Functional ß Cell Mass in Diabetes, 2015-01-29
A redox switch regulates the structure and function of anti-apoptotic BFL-1, 2020-07-13
Direct and selective small-molecule activation of proapoptotic BAX, 2012-05-27
BAX Activation is Initiated at a Novel Interaction Site, 2008-10-23
A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53, 2010-11-16
Generation of Potent and Stable GLP-1 Analoguesvia‘Serine Ligation', 2022-03-23
Identification of a Structural Determinant for Selective Targeting of HDMX, 2020-04-30
Photoreactive Stapled BH3 Peptides to Dissect the BCL-2 Family Interactome, 2010-12-22
Structural basis for defective membrane targeting of mutant enzyme in human VLCAD deficiency, 2022-06-27
MDM2 and MDM4 are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors, 2019-02-12
SWI/SNF mutant cancers depend upon catalytic and non-catalytic activity of EZH2, 2015-11-09
Targeted Disruption of the EZH2/EED Complex Inhibits EZH2-dependent Cancer, 2013-08-25
Site-Dependent Cysteine Lipidation Potentiates the Activation of Proapoptotic BAX, 2020-03-10
Brain and Testicular Tumors in Mice with Progenitor Cells Lacking BAX and BAK, 2012-09-17
Paclitaxel reduces axonal Bclw to initiate IP3R1-dependent axon degeneration, 2017-10-11
A non-apoptotic role for BAX and BAK in eicosanoid metabolism, 2015-04-06
The MCL-1 BH3 Helix is an Exclusive MCL-1 inhibitor and Apoptosis Sensitizer, 2010-06-20
Distinct BimBH3 (BimSAHB) Stapled Peptides for Structural and Cellular Studies, 2014-01-03
Precision Targeting of BFL-1/A1 and an ATM Co-dependency in Human Cancer, 2018-09-25
Focus on Breast Cancer
Locations
Dana-Farber Cancer Institute
Affiliated Hospitals
Compare Providers
Providers shown based on Dr. Walensky's location and specialty. Show more Pediatric Oncologists & Pediatric Hematologists.
Your trust is our top concern. Learn more.
We monitor all reviews to ensure they comply with our guidelines and don’t include personal information, profanity, libel, defamation, harassment, obscenity or fraud.
All reviews are confirmed and audited before publication, and community members have the ability to flag inappropriate content for further review by our team.
Doctors can not pay for good reviews, nor can they pay to have negative reviews removed.
Any reviews that are deemed fraudulent or violate our guidelines will be removed immediately.